Peptide therapy occupies an unusual space in women's health. Some peptides have decades of FDA-approval and rigorous clinical trial data behind them. Others are widely sold online with only preclinical animal data to support their use. For women considering peptide protocols — particularly during the menopausal transition — separating evidence-backed compounds from research-stage ones matters. So does evaluating supplier quality, because the peptide industry remains largely unregulated.
This overview surveys peptides most relevant to menopausal symptoms, grouped by what the literature actually supports. It is not medical advice. It is a research summary intended to inform conversations with qualified clinicians.
FDA-approved peptides relevant to menopause
A small number of peptide-based drugs have FDA approval for indications that overlap with menopausal symptoms. These represent the strongest evidence tier.
Bremelanotide (PT-141, brand name Vyleesi)
Approved by the FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. The RECONNECT trials demonstrated a statistically significant increase in sexual desire and a reduction in distress, though absolute effect sizes were modest. Bremelanotide acts on melanocortin receptors rather than the dopaminergic pathway used by flibanserin. While approved only for premenopausal women, off-label use in postmenopausal women is discussed in some specialty practices.
Tesamorelin (Egrifta)
A growth hormone-releasing hormone analog FDA-approved in 2010 for HIV-associated lipodystrophy. Multiple trials demonstrated reduction in visceral adipose tissue. Off-label use in healthy adults including postmenopausal women is widely discussed in functional medicine, though high-quality trials in non-HIV populations are limited.
Peptides with substantial human research, no menopause-specific indication
Sermorelin and CJC-1295
Growth hormone-releasing peptides studied since the 1980s. Sermorelin was previously FDA-approved for pediatric growth hormone deficiency (discontinued for commercial reasons, not safety). CJC-1295 is a longer-acting analog. Adult use has been studied for body composition and recovery, with mixed results. Neither has specific menopause indications, but both are widely discussed in midlife women's health.
BPC-157
A synthetic pentadecapeptide derived from a gastric protein. Extensive preclinical research demonstrates accelerated tendon, ligament, and gastrointestinal tissue healing in animal models. Human clinical trial data remains limited despite widespread recreational use. For women researching musculoskeletal recovery or gut health, the preclinical case is interesting; the human evidence base is not yet there.
Thymosin Beta-4 (TB-500)
Studied primarily in cardiac and dermal wound healing. Phase II human trials exist but are not yet translated into routine clinical use. Again, intriguing preclinical data; sparse human data.
Peptides with preclinical interest in menopausal symptoms
DSIP (Delta Sleep-Inducing Peptide)
First isolated in 1977. Modulates sleep architecture in animal models with effects on EEG delta wave activity. Limited human trials from the 1980s and 1990s suggested potential for sleep onset and stress modulation, but the research largely stalled. No FDA-approved use.
Epitalon
A four-amino-acid peptide developed in Russian gerontology research. Animal studies suggest telomerase activation and circadian regulation effects. Human evidence consists primarily of small Russian trials with significant methodological limitations. Not approved for any indication in the United States.
Semax and Selank
Both developed in Russia for cognitive and anxiolytic indications respectively. Research is heavily concentrated in Russian-language publications. No FDA approval and no Western RCTs of meaningful size. Sometimes discussed in the context of menopausal cognitive symptoms; the evidence does not currently support routine use.
The supplier quality problem
For any peptide therapy, the question of where the compound was synthesized and how it was tested matters enormously. The peptide market in the United States is largely unregulated. Compounds are sold "for research purposes only" in a regulatory gray zone, and quality varies dramatically — from pharmaceutical-grade manufacturers with mass spectrometry and HPLC verification to anonymous suppliers selling unknown substances.
The variables that distinguish reputable from questionable suppliers include:
- Certificates of Analysis (COAs) — batch-specific lab reports verifying compound identity and purity, typically aiming for ≥99%
- Third-party laboratory testing — independent verification rather than supplier-conducted testing
- Mass spectrometry and HPLC — the gold-standard analytical methods for peptide verification
- Heavy metal and endotoxin testing — particularly important for injected compounds
- Transparent sourcing — manufacturer information, country of synthesis, and supply chain disclosure
Women researching peptide therapy should evaluate at least these five variables before purchasing from any supplier, regardless of marketing claims or social media presence.
What this overview is not
This page is a research summary, not medical advice. Peptide therapy carries real risks — immunogenicity, contamination, off-target effects, and interactions with other medications — and decisions about whether to pursue it should involve qualified clinicians who can evaluate individual health context, contraindications, and goals.
Several of the compounds discussed here are not FDA-approved for any indication and are sold under "research use only" exemptions. The legal status, safety profile, and evidence base differs substantially across the peptides above. Lumping them together as a single category misrepresents the science.
For deeper reading on specific topics, see the related research below.